22-July-2019: The global next generation
sequencing market is expected to reach USD 19.70 billion
by 2025 registering a CAGR of 12.78%, according to a new report by Grand View
Research, Inc. Growing application of NGS methodologies due to rising number of
strategic developments initiated by the market participants is one of the key
drivers of the market. These novel strategies mark the presence of intense
competition between the key firms. Companies are further increasing their
installation base by providing sequencing services in different emerging
countries. For instance, in April 2018, Illumina entered into a partnership
with Loxo Oncology for the development of Illumina TruSight Tumor 170 NGS test
as a companion diagnostic for Loxo Oncology’s LOXO-292 and larotrectinib for
tumor profiling.
Similarly, in March
2018, PierianDx partnered with cancer genetics to offer NGS-based tests for
oncology precision medicine. NGS technologies experience significant growth due
to rapid automation in the pre-sequencing protocols and advancements in
clinical diagnosis and disease testing. Wide application of this technique in
oncology, reproductive screening, infectious disease, noninvasive prenatal
testing, and pharmacogenomics is also expected to positively impact the market
growth. Reduced costs of genetic sequencing has also significantly enhanced the
adoption of these technologies. Reduced installation costs of NGS platforms and
easy availability of proteomic and genomic data has also resulted in an
increased demand, thereby propelling the market development.
In
depth research report on Next Generation Sequencing (NGS) Market
Further key findings from the study suggest:
·
NGS-based platforms & related products account for the
dominant market share due to the presence of sequencing platforms and
instruments required for clinical applications
·
Growing awareness related to NGS services is likely to boost
growth of the services segment
·
Cancer-related genes have a high level of genomic
heterogeneity that can be easily detected by NGS, thus resulting in maximum
revenue flow from the oncology field
·
On the basis of workflow, sequencing vertical accounted for
the largest revenue share of the NGS market in 2018 and is said to continue its
dominance over the forecast period
·
High demand for this technology and usage of NGS platforms
for several research projects and Ph.D. programs contributes to academic
research segment’s growth
·
Whereas, clinical research segment will witness a significant
CAGR owing to emergence of NGS applications in clinical research and studies
·
North American held the maximum revenue share in 2018 due to
the presence of a number of NGS technology providers, such as Illumina and
Thermo Fisher
·
Asia Pacific is expected to emerge as the fastest-growing
region due to continuous improvements laid by key participants in emerging
economies, such as China and India
·
Prominent companies in the global market include Illumina
Inc.; QIAGEN; F Hoffman-La Roche Ltd.; Thermo Fisher Scientific Inc.; and
Bio-Rad Laboratories, Inc.
·
Product development and M&A are some of the key
strategies adopted by these companies, for instance, Illumina acquired Edico
Genome to improve the overall efficiency of NGS solutions provided by Illumina
Grand View Research
has segmented the global next generation sequencing market on the basis of
products & services, application, technology, workflow, end use, and
region:
NGS Products & Services Outlook (Revenue, USD Million,
2014 - 2025)
·
Platforms & Related Products
·
NGS-based Services
NGS Application Outlook (Revenue, USD Million, 2014 - 2025)
·
Oncology
o
Diagnostics and Screening
§
Screening
·
Sporadic Cancer
·
Inherited Cancer
o
Companion Diagnostics
o
Other Diagnostics
o
Research Studies
·
Clinical Investigation
·
Infectious Diseases
·
Inherited Diseases
·
Idiopathic Diseases
·
Non-Communicable/Other Diseases
·
Reproductive Health
·
NIPT
·
Aneuploidy
·
Microdeletions
o
PGT
·
Newborn Genetic Screening
·
Single Gene Analysis
·
HLA Typing/Immune System Monitoring
·
Metagenomics, Epidemiology & Drug Development
·
Agrigenomics & Forensics
·
Consumer Genomics
NGS Technology Outlook (Revenue, USD Million, 2014 - 2025)
·
WGS
·
WES
·
Targeted Sequencing & Resequencing
·
DNA-based
·
RNA-based
NGS Workflow Outlook (Revenue, USD Million, 2014 - 2025)
·
Pre-Sequencing
·
NGS Library Preparation Kits
·
Semi-automated Library Preparation
·
Automated Library Preparation
·
Clonal Amplification
·
Sequencing
·
Data Analysis
·
NGS Primary Data Analysis
·
NGS Secondary Data Analysis
·
NGS Tertiary Data Analysis
NGS End Use Outlook (Revenue, USD Million, 2014 - 2025)
·
Academic Research
·
Clinical Research
·
Hospitals & Clinics
·
Pharma & Biotech Entities
·
Other Users
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment